BlackRock Neurotech

BlackRock Neurotech is a Salt Lake City-based neurotechnology company specializing in the design and manufacture of implantable neural interfaces and research tools for both clinical and scientific applications. The company's flagship product, the Utah Array, is a microelectrode array capable of recording and stimulating neural activity with high spatial resolution, making it one of the most technically advanced tools available for interfacing directly with the brain. BlackRock also produces a broader ecosystem of hardware and software solutions that support neural signal acquisition, processing, and analysis, serving academic research institutions, hospitals, and clinical trial programs worldwide. Their products are built to meet the rigorous demands of both laboratory environments and human implantation, reflecting the company's dual focus on scientific utility and clinical viability.

BlackRock Neurotech holds a uniquely prominent position in the BCI landscape, as the Utah Array has been used in more human BCI implants than any other device in history. This track record spans decades of landmark research, including foundational studies conducted under programs such as BrainGate, where paralyzed patients demonstrated the ability to control robotic limbs and communicate using neural signals alone. The company has raised $10 million in Series B funding, supporting continued product development and the expansion of its clinical and commercial pipeline. These milestones have established BlackRock as a trusted and proven partner for researchers and clinicians pushing the boundaries of what brain-computer interfaces can achieve.

BlackRock Neurotech occupies a critical role in the neurotech industry as the provider of infrastructure that has underpinned much of what the field knows about human neural interfaces. At a time when BCI is attracting unprecedented investment and public attention, the company's decades of validated human implant data represent an asset that few competitors can match. Their technology serves as a foundational platform for advancing therapeutic applications in conditions such as paralysis, epilepsy, and treatment-resistant depression. As the industry moves closer to widespread clinical adoption, BlackRock Neurotech's combination of technical depth, regulatory experience, and proven human use positions it as an indispensable pillar of the emerging brain-computer interface ecosystem.